Blog
Ichor Holdings (ICHR) is a Great Momentum Stock: Should You Buy?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even
What Makes Range Resources (RRC) a New Strong Buy Stock
Range Resources (RRC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces
What Makes Applied Materials (AMAT) a Strong Momentum Stock: Buy Now?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even
Alerus (ALRS) Upgraded to Strong Buy: Here's Why
Alerus (ALRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of
Ametek (AME) Upgraded to Buy: Here's Why
Ametek (AME) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices
What Makes Interface (TILE) a New Buy Stock
Interface (TILE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the
COPT Defense (CDP) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on COPT Defense (CDP), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock
FormFactor (FORM) Is Up 7.64% in One Week: What You Should Know
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
What Makes Apple (AAPL) a Strong Momentum Stock: Buy Now?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Gladstone Capital (GLAD) Upgraded to Buy: What Does It Mean for the Stock?
Gladstone Capital (GLAD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting
Monolithic Power (MPWR) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
What Makes Chatham Lodging (CLDT) a New Strong Buy Stock
Investors might want to bet on Chatham Lodging (CLDT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces
AI and Earnings Lift S&P 500 Outlook: ETFs for Long-Term Growth
Since the onset of the Middle East conflict, volatility has been a persistent theme across global markets, keeping equities choppy and oil prices under pressure. President Donald Trump’s recent
Corning Surges 137.4% Year to Date: How to Play the Stock
Corning Incorporated GLW shares have surged 137.4% year to date compared with the communications components industry’s growth of 119.4%. The stock has outperformed the S&P 500 Index's decline during
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
Johnson & Johnson's JNJ Immunology franchise remains one of its most important businesses, even as it undergoes a transition amid biosimilar competition targeting its multi-billion-dollar product
GLP-1 Wars: Winners & Losers
America’s Obesity Epidemic
One of the most eye-opening exercises you can do is to look at an American beach photo from the 1960s or 1970s and compare it to a beach photo from today. In the early
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
Halozyme Therapeutics HALO reported first-quarter 2026 adjusted earnings of $1.60 per share, which beat the Zacks Consensus Estimate of $1.54. Earnings rose 44.1% year over year.
Total revenues in
Aeva's Q1 Loss Narrower Than Expected on Strong Service Sales
Aeva Technologies, Inc. AEVA posted a narrower-than-expected loss for the first quarter of 2026 as growing commercial deployments drove another record revenue quarter. The company reported an
JPMorgan Chase & Co. (JPM) is a Top Dividend Stock Right Now: Should You Buy?
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is
Cincinnati Financial (CINF) Could Be a Great Choice
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent
Lowe's (LOW) Could Be a Great Choice
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin Down
Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 18 cents in first-quarter 2026, against the year-ago period’s adjusted earnings per share (EPS) of 20 cents and the Zacks
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia Therapeutics NTLA incurred first-quarter 2026 loss of 81 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, the company had incurred


